Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilar Deals 2025
Biosimilars Deals 2023
Biosimilars Deals 2024
Chantal Savage
Chris Vindurampulle
Diversity
Helen Macpherson
Intranet
Kimberley Evans
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
Paul Johns
PipCast®
PTE
Trade Marks
Webinars

Genmab to Acquire Merus in USD 8B Deal

Sep 29, 2025

On 29 September 2025, Genmab A/S and Merus N.V. announced that they have entered into an agreement for Genmab to acquire all the shares of Merus in an all-cash transaction worth approximately USD 8 billion, with the deal anticipated to close early in the first quarter of 2026.

The deal will expand Genmab’s biologics portfolio to include Merus’ petosemtamab (MCLA-158), which is currently in Phase 3 development and has been granted two Breakthrough Therapy Designations by the FDA for recurrent or metastatic programmed death-ligand 1 (PD-L1) positive head and neck squamous cell carcinoma indications.